학술논문

10-year survival in female breast cancer patients according to ER, PR and HER2 expression: a cancer registry population-based analysis.
Document Type
Article
Source
Journal of Cancer Research & Clinical Oncology. Jul2023, Vol. 149 Issue 8, p4489-4496. 8p.
Subject
*BREAST cancer
*CANCER patients
*BREAST cancer prognosis
*FOLLOW-up studies (Medicine)
*TUMOR classification
Language
ISSN
0171-5216
Abstract
Introduction: Invasive breast cancer prognosis has significantly improved over time; however, there are few data about the long-term survival. Materials and methods: We analysed the data on female breast cancer incident during 2004–2005 in the area of the Tuscan Cancer Registry, distinguishing them in five subtypes, according to ER, PgR, HER2, and Ki67 expression: luminal A, luminal B, luminal B/HER2 + , triple-negative, and HER2 +. Effects of subtypes and age on 10 years breast cancer specific survival were analysed by Kaplan–Meier and multivariate Cox analysis. Results: The majority of breast cancer were luminal B (57%), and 45% of them were diagnosed at pathological stage I. The 10-year survival rates (p < 0.001) were higher among luminal A (90.2%) and lower among HER-2 + patients (70.3%). Prognostic effect of age was statistically significant (p < 0.0004): the 10-year cancer specific survival rates were higher among 40–59 years of age patients (88.5%), lower among 0–39 (75.8%). Luminal A breast cancer patients had a constant low risk throughout 10 years of follow up, while luminal B/HER2 + and triple negative tumours showed a peak 5 years after the diagnosis and then declined. Discussion: Our study confirmed the prognostic effect of biological subtype also in a long term follow up study; moreover, age at diagnosis showed to influence the outcome, other than stage at diagnosis and treatment. The long term follow up showed a constant risk of death for luminal A and B tumours, whereas for non-luminal cancer a peak 5 years after the diagnosis was found. [ABSTRACT FROM AUTHOR]